Incyte Reports Topline Data from P-III (STOP-HS1 & STOP-HS2) Trials of Povorcitinib (INCB054707) for Hidradenitis Suppurativa (HS)
Shots:
- The 2 P-III (STOP-HS1 & STOP-HS2) trials assessed povorcitinib (45 or 75mg, QD, PO) vs PBO in mod. to sev. HS pts (≥18yrs.; n=600 each) for 12wks., followed by 42wk. extension & 30-day follow-up
- STOP-HS1 met its 1EP, with povorcitinib (45 mg/75 mg) showing higher HiSCR50 rates at Wk. 12 (40.2%/40.6% vs 29.7%), while a biologics-experienced subgroup also showed higher response (34.2%/37.8% vs 21.9%), with >3-pt. Skin Pain NRS reductions (incl. NRS30), fewer flares, & rapid onset
- STOP-HS2 also met its 1EP of superior HiSCR50 rates at Wk. 12 (42.3%/42.3% vs 28.6%), with higher response in mentioned subgroup (45.0%/40.0% vs 19.5%); data to support regulatory filings & presented at future meetings
Ref: Incyte | Image: Incyte
Related News:- Incyte Highlights P-III (TRuE-PN) Clinical Program Data of Opzelura (1.5% Ruxolitinib Cream) for Prurigo Nodularis (PN) at AAD 2025
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
